Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

6.55USD
22 Sep 2017
Change (% chg)

$0.05 (+0.77%)
Prev Close
$6.50
Open
$6.49
Day's High
$6.64
Day's Low
$6.44
Volume
270,418
Avg. Vol
742,457
52-wk High
$8.84
52-wk Low
$1.51

Latest Key Developments (Source: Significant Developments)

ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock
Friday, 1 Sep 2017 08:00am EDT 

Sept 1 (Reuters) - ImmunoGen Inc :ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock.ImmunoGen Inc - ‍Company anticipates that exchanges will be completed on or about September 11, 2017​.ImmunoGen Inc - Aggregate principal amount of company's 4.50% convertible senior notes due 2021 is anticipated to be reduced to approximately $23.6 million​.ImmunoGen Inc - Co ‍will exchange about 16.5 million newly issued shares of company's common stock​.  Full Article

Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products
Tuesday, 29 Aug 2017 06:30am EDT 

Aug 29 (Reuters) - Immunogen Inc :Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products.Immunogen will be responsible for development of three ADC programs prior to any potential opt-in by Jazz.Immunogen Inc - as part of agreement, Jazz will pay Immunogen an upfront payment of $75 million.Immunogen Inc - additionally, Jazz will pay Immunogen up to $100 million in development funding over seven years to support three ADC programs.Immunogen - After any opt-in, Jazz would be responsible for any further development as well as for potential regulatory submissions, commercialization.Immunogen - Programs covered under agreement include IMGN779, a CD33-targeted ADC for treatment of acute myeloid leukemia (AML) in Phase 1 testing.Immunogen - Programs under deal also include IMGN632, a CD123-targeted ADC for hematological malignancies seen to enter clinical testing before end of year.  Full Article

ImmunoGen reports recent progress and second quarter 2017 operating results
Friday, 28 Jul 2017 06:30am EDT 

July 28 (Reuters) - Immunogen Inc :Q2 loss per share $0.10.Q2 revenue $39 million versus $7.4 million.Q2 revenue view $30.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $115 million to $120 million.ImmunoGen Inc - ‍operating expenses remain unchanged and are expected to be between $175 million and $180 million for 2017​.ImmunoGen - ‍expects current cash plus expected cash revenues from partners and collaborators will enable co to fund operations into second half of 2018​.FY2017 revenue view $92.0 million -- Thomson Reuters I/B/E/S.ImmunoGen Inc - ‍cash and cash equivalents at December 31, 2017 are expected to be between $90 million and $95 million​.  Full Article

Immunogen and Sanofi amend license agreements
Tuesday, 30 May 2017 08:30am EDT 

May 30 (Reuters) - Immunogen Inc :Immunogen and Sanofi amend license agreements.Immunogen - co, affiliate of Sanofi have amended their license agreements covering all compounds in development by sanofi using Immunogen's technology.Immunogen Inc - as consideration for these amendments, Immunogen will receive a $30 million payment.Immunogen - as consideration for amendments immunogen agreed to forego limited co-promotion option in U.S. With respect to compounds covered by 2003 agreement.Immunogen - as consideration for amendments immunogen has also agreed to forego future milestones or royalties under both license agreements.Immunogen Inc - also amended to grant Sanofi fully-paid, exclusive license to develop, manufacture, commercialize experimental compound SAR428926.  Full Article

Immunogen reports Q1 loss per share of $0.20
Friday, 5 May 2017 06:38am EDT 

May 5 (Reuters) - Immunogen Inc ::Immunogen reports recent progress and first quarter 2017 operating results.Q1 loss per share $0.20.Q1 revenue $28.5 million versus $19.7 million.Q1 revenue view $16.2 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Financial guidance for 2017 remains unchanged from that issued in February 2017.FY 2017 earnings per share view $-1.42, revenue view $66.2 million -- Thomson Reuters I/B/E/S.Expects that its current cash plus expected cash revenues will enable company to fund operations into q2 of 2018.  Full Article

Immunogen files for mixed shelf of up to $200 mln – SEC filing
Friday, 3 Mar 2017 04:23pm EST 

Immunogen Inc :Immunogen Inc files for mixed shelf of up to $200 million – sec filing.  Full Article

Immunogen sees FY 2017 revenue $70 mln to $75 mln
Friday, 17 Feb 2017 06:30am EST 

Immunogen Inc : Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016 . Sees FY 2017 revenue $70 million to $75 million . Immunogen Inc - first patient enrolled in phase 3 forward I trial of mirvetuximab soravtansine . Immunogen Inc - sees 2017 revenues between $70 million and $75 million . Immunogen Inc - sees 2017 operating expenses between $175 million and $180 million . Immunogen Inc -sees cash and marketable securities at December 31, 2017 between $35 million and $40 million .Immunogen - expects current cash plus expected cash revenues from partners and collaborators will enable company to fund operations into Q2 of 2018.  Full Article

US appeals court dismisses Phigenix appeal in patent lawsuit vs Immunogen
Monday, 9 Jan 2017 09:41am EST 

Immunogen Inc : u.s. Appeals court dismisses phigenix inc appeal in patent infringement lawsuit against immunogen inc -- court ruling . u.s. Court of appeals for federal circuit says phigenix lacks standing to sue because it lacked sufficient proof of injury . Lawsuit related to patent intended to help combat a variety of cancers -- ruling Further company coverage: [IMGN.O].  Full Article

Immunogen quarterly loss $0.51 per share
Friday, 28 Oct 2016 06:39am EDT 

Immunogen Inc : Immunogen reports financial results for quarter ended September 30 and reviews business highlights . Quarterly loss per share $0.51 . Quarterly revenue $7.7 million versus $14.9 million . Immunogen Inc - Expected revenues for six months ending December 31, 2016 now projected to be between $25 million and $30 million . Immunogen Inc - Net loss for six months ending December 31, 2016 now expected to be between $70 million and $75 million .Immunogen - Operating expenses in quarter correspondingly include $4.1 million restructuring charge,includes costs related to 17 percent workforce reduction.  Full Article

Immunogen: Will reduce workforce by 17 pct
Thursday, 29 Sep 2016 04:01pm EDT 

Immunogen Inc : Company will reduce its workforce by 17 pct and seek to partner its non-core b-cell lymphoma programs . Through this plan, Immunogen will realize significant cost savings over next two years in headcount, program, and support activities . These savings will include approximately $11 million per year relating to elimination of 65 positions . Expects to achieve previously-stated goal of funding operations through analysis of mirvetuximab soravtansine pivotal trial,into mid-2018 . As a result of workforce reduction, immunogen will record a one-time charge totaling approximately $3.5 million .As part of this effort and prioritization of its ign programs, will seek to monetize its non-core b-cell assets through partnering with interested parties.  Full Article

BRIEF-ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock

* ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock